Alaunos Therapeutics, Inc.(TCRT)Earnings, Financials & Key Ratios
TCRT•NASDAQ
$2.63
$6M mkt cap·Price updated May 6, 2026
AboutAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.Show more
- Revenue$10K+100.0%
- EBITDA-$5M+84.9%
- Net Income-$5M+86.7%
- EPS (Diluted)-2.92+86.7%
- Gross Margin100%+100.1%
- EBITDA Margin-48100%+92.5%
- Operating Margin-48120%+93.0%
- Net Margin-46790%+93.3%
- ROE-111.8%+28.6%
- ROIC-593.1%-128.6%
TCRT Key Insights
Alaunos Therapeutics, Inc. (TCRT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TCRT Price & Volume
Alaunos Therapeutics, Inc. (TCRT) stock price & volume — 10-year historical chart
Loading chart...
TCRT Growth Metrics
Alaunos Therapeutics, Inc. (TCRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-38.87%
5 Years-
3 Years-70.71%
TTM0%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM65.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM68.61%
Return on Capital
10 Years-94.12%
5 Years-93.17%
3 Years-106.42%
Last Year-114.98%
TCRT Peer Comparison
Alaunos Therapeutics, Inc. (TCRT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 TCRX | 162.39M | 1.25 | -1.25 | 266.65% | -15.24% | -91.94% | 0.76 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 CRIS | 81.2M | 0.62 | -1.06 | -13.43% | -80.29% | -138.81% | 0.30 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 |
Compare TCRT vs Peers
Alaunos Therapeutics, Inc. (TCRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TCRT Income Statement
Alaunos Therapeutics, Inc. (TCRT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.86M | 6.39M | 146K | 0 | 0 | 398K | 2.92M | 5K | 10K | 6K |
| Revenue Growth % | 58.38% | -6.88% | -97.71% | -100% | - | - | 634.17% | -99.83% | 100% | 0% |
| Cost of Goods Sold | 0 | 0 | 0 | 629K | 1.13M | 0 | 0 | 4.8M | 0 | 185K |
| COGS % of Revenue | - | - | - | - | - | - | - | 96060% | - | - |
| Gross Profit | 6.86M▲ 0% | 6.39M▼ 6.9% | 146K▼ 97.7% | -629K▼ 530.8% | -1.13M▼ 79.3% | 398K▲ 135.3% | 2.92M▲ 634.2% | -4.8M▼ 264.2% | 10K▲ 100.2% | -179K▲ 0% |
| Gross Margin % | 100% | 100% | 100% | - | - | 100% | 100% | -95960% | 100% | -2983.33% |
| Gross Profit Growth % | 58.38% | -6.88% | -97.71% | -530.82% | -79.33% | 135.28% | 634.17% | -264.2% | 100.21% | - |
| Operating Expenses | 172.17M | 59.88M | 54.05M | 57.23M | 79.23M | 77.95M | 38.03M | 29.47M | 4.82M | 3.89M |
| OpEx % of Revenue | 2509.37% | 937.27% | 37021.92% | - | - | 19584.67% | 1301.4% | 589380% | 48220% | - |
| Selling, General & Admin | 14.38M | 14.8M | 19.92M | 18.9M | 26.54M | 27.56M | 13.14M | 12.22M | 4.46M | 3.16M |
| SG&A % of Revenue | 209.55% | 231.62% | 13642.47% | - | - | 6925.63% | 449.76% | 244380% | 44600% | - |
| Research & Development | 157.79M | 45.08M | 34.13M | 38.33M | 52.7M | 49.64M | 25.02M | 16.28M | 362K | 915K |
| R&D % of Revenue | 2299.83% | 705.65% | 23379.45% | - | - | 12473.12% | 856.19% | 325580% | 3620% | - |
| Other Operating Expenses | 134K | 465K | 0 | 0 | 0 | 740K | -133K | 971K | 0 | -185K |
| Operating Income | -165.31M▲ 0% | -53.49M▲ 67.6% | -53.91M▼ 0.8% | -57.86M▼ 7.3% | -80.36M▼ 38.9% | -77.55M▲ 3.5% | -35.1M▲ 54.7% | -34.27M▲ 2.4% | -4.81M▲ 86.0% | -4.07M▲ 0% |
| Operating Margin % | -2409.37% | -837.27% | -36921.92% | - | - | -19484.67% | -1201.4% | -685340% | -48120% | -67883.32% |
| Operating Income Growth % | -37.64% | 67.64% | -0.77% | -7.33% | -38.89% | 3.5% | 54.73% | 2.39% | 85.96% | - |
| EBITDA | -165.02M | -53.12M | -53.33M | -57.23M | -79.23M | -74.95M | -32.35M | -31.95M | -4.81M | -4.03M |
| EBITDA Margin % | -2405.14% | -831.49% | -36529.45% | - | - | -18832.16% | -1106.98% | -639040% | -48100% | -67108.33% |
| EBITDA Growth % | -37.81% | 67.81% | -0.39% | -7.31% | -38.45% | 5.4% | 56.84% | 1.22% | 84.95% | 65.7% |
| D&A (Non-Cash Add-back) | 290K | 369K | 573K | 629K | 1.13M | 2.6M | 2.76M | 2.31M | 2K | -501 |
| EBIT | -165.31M | -53.49M | -53.91M | -117.8M | -79.98M | -77.56M | -34.58M | -33.22M | -4.68M | -4.01M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | -1.19M | -3.15M | -1.92M | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 830K | 0 | 0 | 0 | 1.19M | 3.15M | 1.92M | 0 | 0 |
| Other Income/Expense | 10K | -830K | 789K | -59.94M | 385K | -1.2M | -2.63M | -873K | 133K | 48K |
| Pretax Income | -165.3M▲ 0% | -54.32M▲ 67.1% | -53.12M▲ 2.2% | -117.8M▼ 121.8% | -79.98M▲ 32.1% | -78.75M▲ 1.5% | -37.73M▲ 52.1% | -35.14M▲ 6.9% | -4.68M▲ 86.7% | -4.03M▲ 0% |
| Pretax Margin % | -2409.23% | -850.26% | -36381.51% | - | - | -19786.68% | -1291.24% | -702800% | -46790% | -67083.33% |
| Income Tax | 114K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.07% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -165.3M▲ 0% | -54.32M▲ 67.1% | -53.12M▲ 2.2% | -117.8M▼ 121.8% | -79.98M▲ 32.1% | -78.75M▲ 1.5% | -37.73M▲ 52.1% | -35.14M▲ 6.9% | -4.68M▲ 86.7% | -4.03M▲ 0% |
| Net Margin % | -2409.23% | -850.26% | -36381.51% | - | - | -19786.68% | -1291.24% | -702800% | -46790% | -67083.33% |
| Net Income Growth % | -37.65% | 67.14% | 2.22% | -121.77% | 32.11% | 1.53% | 52.09% | 6.86% | 86.68% | 65.83% |
| Net Income (Continuing) | -165.3M | -54.32M | -53.12M | -117.8M | -79.98M | -78.75M | -37.73M | -35.14M | -4.68M | -4.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -190.15▲ 0% | -59.50▲ 68.7% | -55.44▲ 6.8% | -158.90▼ 186.6% | -56.42▲ 64.5% | -53.80▲ 4.6% | -25.97▲ 51.7% | -21.97▲ 15.4% | -2.92▲ 86.7% | -1.84▲ 0% |
| EPS Growth % | -32.39% | 68.71% | 6.82% | -186.62% | 64.49% | 4.64% | 51.73% | 15.4% | 86.71% | 68.61% |
| EPS (Basic) | -190.15 | -59.50 | -55.52 | -158.90 | -56.42 | -53.80 | -25.97 | -21.97 | -2.92 | - |
| Diluted Shares Outstanding | 869.28K | 912.92K | 956.72K | 1.12M | 1.4M | 1.43M | 1.45M | 1.6M | 1.6M | 2.18M |
| Basic Shares Outstanding | 869.28K | 912.92K | 956.72K | 1.12M | 1.4M | 1.43M | 1.45M | 1.6M | 1.6M | 2.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TCRT Balance Sheet
Alaunos Therapeutics, Inc. (TCRT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 104.88M | 90.78M | 84.28M | 105.49M | 130.59M | 78.83M | 53.8M | 8.26M | 2.75M | 2.69M |
| Cash & Short-Term Investments | 81.05M | 70.95M | 61.73M | 79.74M | 115.07M | 76.05M | 39.06M | 6.06M | 1.09M | 1.94M |
| Cash Only | 81.05M | 70.95M | 61.73M | 79.74M | 115.07M | 76.05M | 39.06M | 6.06M | 1.09M | 1.94M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 21K | 19K | 1.86M | 3.33M | 4.67M | 1.11M | 4K | 1K | 5K | 0 |
| Days Sales Outstanding | 1.12 | 1.09 | 4.66K | - | - | 1.02K | 0.5 | 73 | 182.5 | 136.88 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 13.94M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 23.81M | 0 | 20.69M | 0 | 0 | 1.67M | 799K | 2.2M | 1.66M | 747K |
| Total Non-Current Assets | 1.46M | 14.82M | 10.77M | 3.62M | 15.76M | 16.03M | 11.14M | 2K | 0 | 1.04M |
| Property, Plant & Equipment | 843K | 1.21M | 1.1M | 3.38M | 14.88M | 15.36M | 10.6M | 2K | 0 | 97K |
| Fixed Asset Turnover | 8.14x | 5.28x | 0.13x | - | - | 0.03x | 0.28x | 2.50x | - | 0.25x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 620K | 104K | 105K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1K | 13.51M | 9.56M | 240K | 875K | 673K | 542K | 0 | 0 | 2.99M |
| Total Assets | 106.35M▲ 0% | 105.61M▼ 0.7% | 95.05M▼ 10.0% | 109.11M▲ 14.8% | 146.34M▲ 34.1% | 94.86M▼ 35.2% | 64.94M▼ 31.5% | 8.26M▼ 87.3% | 2.75M▼ 66.7% | 3.72M▲ 0% |
| Asset Turnover | 0.06x | 0.06x | 0.00x | - | - | 0.00x | 0.04x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | -30.82% | -0.7% | -9.99% | 14.8% | 34.12% | -35.18% | -31.55% | -87.28% | -66.66% | -125.42% |
| Total Current Liabilities | 15.81M | 20.86M | 9.48M | 12.53M | 18.37M | 16.04M | 24.17M | 1.96M | 692K | 921K |
| Accounts Payable | 156K | 4.42M | 707K | 906K | 960K | 1.37M | 1.39M | 616K | 516K | 843K |
| Days Payables Outstanding | - | - | - | 525.74 | 310.64 | - | - | 46.81 | - | 1.48K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 8.6M | 17.32M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 6.39M | 6.39M | 13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.6M | 2.06M | 6.63M | 1.91M | 13.28M | 3.65M | 3.74M | 1.3M | 0 | 0 |
| Current Ratio | 6.63x | 4.35x | 8.89x | 8.42x | 7.11x | 4.91x | 2.23x | 4.22x | 3.98x | 3.98x |
| Quick Ratio | 6.63x | 4.35x | 8.89x | 8.42x | 7.11x | 4.91x | 1.65x | 4.22x | 3.98x | 3.98x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.34K |
| Total Non-Current Liabilities | 42.52M | 37.56M | 4K | 1.58M | 4M | 20.77M | 2.22M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 16.25M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 1.58M | 4M | 4.52M | 2.19M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 988K | 2.42M | 0 | 0 | 0 | -1K | 28K | 0 | 0 | 0 |
| Total Liabilities | 183.65M | 202.41M | 9.49M | 14.1M | 22.36M | 36.81M | 26.38M | 1.96M | 692K | 921K |
| Total Debt | 0 | 0 | 0 | 2.35M | 4.81M | 30.09M | 20.07M | 0 | 0 | 0 |
| Net Debt | -81.05M | -70.95M | -61.73M | -77.39M | -110.25M | -45.96M | -18.99M | -6.06M | -1.09M | -1.94M |
| Debt / Equity | - | - | - | 0.02x | 0.04x | 0.52x | 0.52x | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.48x |
| Interest Coverage | - | -64.45x | - | - | - | -65.22x | -11.13x | -17.84x | - | - |
| Total Equity | -77.3M▲ 0% | -96.81M▼ 25.2% | 85.56M▲ 188.4% | 95.01M▲ 11.0% | 123.98M▲ 30.5% | 58.06M▼ 53.2% | 38.55M▼ 33.6% | 6.31M▼ 83.6% | 2.06M▼ 67.3% | 2.8M▲ 0% |
| Equity Growth % | -188.47% | -25.24% | 188.39% | 11.04% | 30.49% | -53.17% | -33.59% | -83.64% | -67.29% | -145.25% |
| Book Value per Share | -88.92 | -106.04 | 89.43 | 84.85 | 88.71 | 40.62 | 26.63 | 3.94 | 1.29 | 1.28 |
| Total Shareholders' Equity | -77.3M | -96.81M | 85.56M | 95.01M | 123.98M | 58.06M | 38.55M | 6.31M | 2.06M | 2.8M |
| Common Stock | 132K | 143K | 161K | 182K | 215K | 216K | 240K | 16K | 2K | 2K |
| Retained Earnings | -658M | -712.44M | -566.33M | -684.13M | -764.1M | -842.85M | -880.63M | -915.77M | -920.45M | -923.73M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -125.32M | -143.99M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRT Cash Flow Statement
Alaunos Therapeutics, Inc. (TCRT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -58.33M | -54.67M | -49.46M | -40.85M | -57.01M | -61.47M | -29.23M | -30.14M | -4.97M | -4.97M |
| Operating CF Margin % | -850.09% | -855.67% | -33874.66% | - | - | -15444.22% | -1000.41% | -602840% | -49710% | - |
| Operating CF Growth % | -583150% | 6.27% | 9.53% | 17.39% | -39.55% | -7.81% | 52.44% | -3.11% | 83.51% | 201.94% |
| Net Income | -165.3M | -54.32M | -53.12M | -117.8M | -79.98M | -78.75M | -37.73M | -35.14M | -4.68M | -4.03M |
| Depreciation & Amortization | 290K | 369K | 575K | 629K | 1.13M | 2.6M | 2.76M | 2.31M | 2K | -1K |
| Stock-Based Compensation | 8.45M | 8.45M | 7.53M | 7.34M | 6.83M | 10.77M | 3.53M | 2.8M | 435K | 460K |
| Deferred Taxes | 124K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 119.02M | 1.29M | -158K | 60.75M | 0 | 771K | 1.34M | 6.14M | 0 | 205K |
| Working Capital Changes | -20.92M | -10.46M | -4.29M | 8.22M | 15.01M | 3.14M | 870K | -6.25M | -729K | 452K |
| Change in Receivables | 425K | 2K | -1.84M | -1.47M | -1.33M | 3.56M | 1.11M | 3K | -4K | 0 |
| Change in Inventory | -12.25M | 0 | 1.53M | 1.47M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.85M | 4.26M | -3.71M | 199K | 54K | 274K | -25K | -773K | -100K | 386K |
| Cash from Investing | -551K | -737K | -459K | -284K | -9.78M | -3.32M | -193K | 1.35M | 0 | -97K |
| Capital Expenditures | -551K | -737K | -459K | -284K | -9.78M | -3.32M | -216K | -197K | 0 | -97K |
| CapEx % of Revenue | 8.03% | 11.54% | 314.38% | - | - | 834.92% | 7.39% | 3940% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -737K | 0 | 0 | 0 | 0 | 23K | 1.54M | 0 | 0 |
| Cash from Financing | -788K | 45.3M | 40.31M | 59.15M | 102.12M | 25.78M | 6.37M | -18.14M | 0 | 3.26M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 25M | -8.33M | -18.11M | 0 | 0 |
| Equity Issued (Net) | -1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 92K | 0 | 1000K |
| Dividends Paid | -7.12M | 0 | -17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -1.5M | -2.06M | -1.62M | -653K | 0 | 0 | -45K | 0 | 0 | 0 |
| Other Financing | 7.84M | 88K | 11.83M | 53.72M | 442K | 776K | 21K | -125K | 0 | 0 |
| Net Change in Cash | -59.66M▲ 0% | -10.11M▲ 83.1% | -9.61M▲ 5.0% | 18.01M▲ 287.5% | 35.33M▲ 96.1% | -39.02M▼ 210.4% | -23.06M▲ 40.9% | -46.93M▼ 103.5% | -4.97M▲ 89.4% | 255K▲ 0% |
| Free Cash Flow | -58.88M▲ 0% | -55.41M▲ 5.9% | -49.92M▲ 9.9% | -41.14M▲ 17.6% | -66.79M▼ 62.4% | -64.79M▲ 3.0% | -29.45M▲ 54.5% | -30.34M▼ 3.0% | -4.97M▲ 83.6% | -3.01M▲ 0% |
| FCF Margin % | -858.13% | -867.21% | -34189.04% | - | - | -16279.15% | -1007.8% | -606780% | -49710% | -50100% |
| FCF Growth % | -13851.66% | 5.89% | 9.91% | 17.59% | -62.36% | 2.99% | 54.55% | -3.03% | 83.62% | 74.45% |
| FCF per Share | -67.73 | -60.69 | -52.17 | -36.74 | -47.79 | -45.33 | -20.34 | -18.97 | -3.10 | -3.10 |
| FCF Conversion (FCF/Net Income) | 0.35x | 1.01x | 0.93x | 0.35x | 0.71x | 0.78x | 0.77x | 0.86x | 1.06x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 630K | 2.17M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRT Key Ratios
Alaunos Therapeutics, Inc. (TCRT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -3281.98% | - | -62.08% | -130.47% | -73.04% | -86.52% | -78.11% | -156.66% | -111.8% | -167.97% |
| Return on Invested Capital (ROIC) | - | - | - | -209.35% | -384.53% | -450.45% | -166.31% | -259.45% | -593.1% | -593.1% |
| Gross Margin | 100% | 100% | 100% | - | - | 100% | 100% | -95960% | 100% | -2983.33% |
| Net Margin | -2409.23% | -850.26% | -36381.51% | - | - | -19786.68% | -1291.24% | -702800% | -46790% | -67083.33% |
| Debt / Equity | - | - | - | 0.02x | 0.04x | 0.52x | 0.52x | - | - | 0.00x |
| Interest Coverage | - | -64.45x | - | - | - | -65.22x | -11.13x | -17.84x | - | - |
| FCF Conversion | 0.35x | 1.01x | 0.93x | 0.35x | 0.71x | 0.78x | 0.77x | 0.86x | 1.06x | 0.75x |
| Revenue Growth | 58.38% | -6.88% | -97.71% | -100% | - | - | 634.17% | -99.83% | 100% | 0% |
TCRT Frequently Asked Questions
Alaunos Therapeutics, Inc. (TCRT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue for fiscal year 2024. This represents a 248% increase from $0.0M in 2001.
Alaunos Therapeutics, Inc. (TCRT) grew revenue by 100.0% over the past year. This is strong growth.
Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.0M for fiscal year 2024.
Dividend & Returns
Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -111.8%. Negative ROE indicates the company is unprofitable.
Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $3.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More TCRT
Alaunos Therapeutics, Inc. (TCRT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates